Aprotinin Reduces Blood Loss after Cardiopulmonary Bypass by Direct Inhibition of Plasmin

Summary

The effectiveness and mechanism of aprotinin reduced bleeding after cardiopulmonary bypass surgery was studied in a double blind randomised study of 106 patients undergoing valve replacement surgery. Aprotinin therapy was associated with significant reduction in perioperative bleeding and postoperative blood transfusion requirements. Although initially tissue plasminogen activator (t-PA) activity was lower in the aprotinin than placebo group, as surgery proceeded this difference was reversed due to less plasminogen activator inhibitor-1 release in the aprotinin group. This indicates that aprotinin-mediated suppression of fibrinolysis as demonstrated by reduced D-dimer concentration was not related to t-PA. Furthermore, similar perioperative reduction of plasminogen levels in aprotinin and placebo groups indicated a similar degree of conversion of plasminogen to plasmin. However, less plasmin bound with alpha 2-antiplasmin in the plasma in the aprotinin group as it was already complexed with aprotinin where it remained protected from the natural inhibitor on the intact fibrin surface. The reduced fibrinolytic activity of the aprotinin group was thus brought about by the complexing of aprotinin with the plasmin which was bound to the fibrin surface.

• References

• 1 Blanchard A, Humi M, Ruchat P, Stumpe F, Fischer A, Sadeghi H. Incidence of deep and superficial sternal infection after open heart surgery. A ten years retrospective study from 1981 to 1991. Eur J Cardiothorac Surg 1995; 09: 153-157
• 2 Gram J, Janetzko T, Jesperson J, Bruhn HD. Enhanced effective fibrinolysis following the neutralisation of heparin in open heart surgery increases the risk of post-surgical bleeding. Thromb Haemost 1990; 63: 241-245
• 3 Teufelsbauer H, Proidl MH, Vukovich T. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992; 68: 250-252
• 4 Orchard M, Goodchild C, Prentice C, Davies J, Benoit S, Creighton KL, Gaffney P, Michelson A. Aprotinin reduces cardiopulmonary bypass induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol. 1993; 85: 533-541
• 5 Wahba A, Black G, Koksch M, Rothe G, Preuner J, Schmitz G, Bimbaum DE. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. Thromb Haemost 1996; 75: 844-848
• 6 Ray MJ, Marsh NA, Just SJE, Perrin EJ, O’Brien MF, Hawson GAT. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass. Ann Thorac Surg 1997; 63: 57-63
• 7 Ray MJ, Marsh NA, Hawson GAT. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass. Blood Coag Fibrinol 1994; 05: 679-685
• 8 Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothor Anaesth 1989; 03: 181-188
• 9 Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass – effects on the Hageman factor (FXII)-kallikrein system and blood loss. Blood Coag Fibrinol 1992; 03: 099-104
• 10 Kongsgaard U, Smith-Erichsen N, Geiran O, Bjomskau L. Changes in the coagulation and fibrinolytic systems during and after cardiopulmonary bypass surgery. Thorac Cardiovasc Surg 1989; 37: 158-162
• 11 Khuri S, Wolfe J, Josa M, et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg. 1992; 104: 094-107
• 12 Dietrich W, Spannagl M, Jochum M, et al. Influence of high dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990; 73: 1119-1126
• 13 Bidstrup B, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55: 971-976
• 14 Lavee J, Raviv Z, Smolinsky A, et al. Platelet protection by low dose aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1993; 55: 114-119
• 15 Havel M, Griesmacher A, Weigel G, et al. Aprotinin increases release of von Willebrand factor in cultured human umbilical vein endothelial cells. Surgery 1992; 112: 573-577
• 16 Stibbe J, Kluft C, Brommer EJP, Gomes M, de Jong DS, Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 375-382
• 17 Chandler WL, Fitch JCK, Wall MH, Verrier ED, Cochran RP, Soltow LO, Spiess BD. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995; 74: 1293-1297
• 18 Chandler W. The effect of cardiopulmonary bypass on fibrin formation and lysis: Is a normal fibrinolytic response essential? J Cardiovasc Pharmacol. 1996; 27: S63-S68
• 19 Royston D. Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J Cardiovasc Pharmacol 1996; 27: S42-S49
• 20 Royston D. The serine antiprotease aprotinin (Trasylol™): a novel approach to reduce postoperative bleeding. Blood Coag Fibrinol 1990; 01: 55-69
• 21 Voss R, Matthias FR, Borkowski G, Reitz D. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 1990; 75: 099-105
• 22 Longstaff C. Studies in the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coag Fibrinol 1994; 05: 537-542
• 23 Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional action of aprotinin? J Cardiovasc Pharmacol. 1996; 27: S50-S57
• 24 Broze GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93
• 25 Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, Smith KJ. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82: 3350-3357
• 26 Francis JL, Howard C. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin. Blood Coag Fibrinol 1993; 04: 35-40
• 27 Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celiteand kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology 1995; 83: 679-689